Biotech

All Articles

Bicara, Zenas find IPOs to push late-phase properties towards market

.Bicara Therapeutics and also Zenas Biopharma have offered clean motivation to the IPO market along ...

Genentech to close cancer immunology investigation team

.Genentech is going to close its cancer immunology investigation team, as well as system mind and po...

Kezar goes down sound lump however to prove its own truly worth in phase 1 trial

.Kezar Lifestyle Sciences is falling its own dim period 1 solid growth drug as the biotech goes all-...

Acelyrin loses izokibep, drops 3rd of staff

.Even with izokibep sustaining its own newly found winning touch in the facility, Acelyrin is no mor...

Rivus' period 2 obesity-related heart failure trial strikes endpoint

.Rivus Pharmaceuticals has actually plumped up the prospects of its fat-busting, muscle-sparing medi...

Ovid standstills preclinical work, IV course after soticlestat fall short

.Ovid Therapy actually showed final month that it was actually trimming its own headcount as the com...

Eli Lilly opens up $700M nucleic acid R&ampD center in Boston Seaport

.Eli Lilly has opened up a $700 million R&ampD center in the Boston Seaport, improving its RNA as we...

Boundless Biography produces 'small' layoffs five months after $100M IPO

.Simply five months after getting a $100 million IPO, Vast Bio is actually already giving up some em...

Halda's $126M will progress 'hold and kill' growth drugs

.The preliminary phases of oncology R&ampD may not be except interesting brand new modalities, and a...

Lykos 'regrets' certainly not disclosing research study infractions with author

.Psychopharmacology has actually drawn 3 short articles concerning midstage scientific trial data de...